HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time
October 25 2022 - 8:31AM
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, will hold a
conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern
time to discuss its results for the third quarter ended September
30, 2022, and will be reviewing recent announcements, ongoing
initiatives, and key 2022 and anticipated 2023 milestones. A press
release detailing these results will be issued prior to the
call.
HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard
Brounstein, and CBO Jon Hunt, PhD, will host the conference call,
followed by a question-and-answer period. The conference call will
be accompanied by a presentation, which can be viewed during the
webcast or accessed via the investor relations section of the
Company’s website here.
To access the call, please use the following information:
Date:
Thursday November 10, 2022
Time:
4:30 p.m. Eastern time (1:30 p.m.
Pacific time)
Dial-in:
1-800-458-4121
International Dial-in:
1-646-828-8193
Conference Code:
7787050
Webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1576186&tp_key=0aec66c6b6
A telephone replay will be available approximately two hours
after the call and will run through February 10, 2023, by dialing
1-844-512-2921 from the U.S., or 1-412-317-6671 from international
locations, and entering replay pin number: 7787050. The replay can
also be viewed through the webcast link above and the presentation
utilized during the call will be available in the company’s
investor relations section here.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221025005427/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact: Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Apr 2023 to Apr 2024